Get notified of page updates

Treatment study for people diagnosed with metastatic pancreatic cancer with Homologous Recombination Deficiency, or whose disease has responded well to first-line or second-line platinum therapy

Clinicaltrials.gov identifier:
NCT04666740
PRINTER FRIENDLY PAGE

Pembrolizumab and Olaparib for People With Metastatic Pancreatic Cancer with Homologous Recombination Deficiency or Exceptional Response to Platinum Chemotherapy

Treatment study for people diagnosed with metastatic pancreatic cancer with Homologous Recombination Deficiency, or whose disease has responded well to first-line or second-line platinum therapy

Clinicaltrials.gov identifier:
NCT04666740
PRINTER FRIENDLY PAGE
Overview
Who Can Join
Glossary on
off

About the Study

NOTE: This study is no longer recruiting people. 

 

This is a study for people diagnosed with pancreatic cancer with , or whose disease has responded well to or second-line platinum therapy. The goal of this study is to look at whether combining the  drug, pembrolizumab and the ,  is a more effective treatment for this cancer than taking olaparib alone.

 

This Study is Open To:

NOTE: This study is no longer recruiting people.

This Study is NOT Open To:

NOTE: This study is no longer recruiting people.